The APPL1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous population of A-549 human non-small cell lung adenocarcinoma cells featuring functional disruption of the APPL1 gene. This polyclonal knockout pool enables the study of APPL1-dependent cellular processes without the confounding effects of clonal selection. Loss-of-function of APPL1, an adaptor protein with critical roles in signal transduction and endosomal trafficking, provides a versatile model for dissecting its contributions to oncogenic signaling networks.
The host A-549 cell line was originally derived from a human lung adenocarcinoma and serves as a widely used model for non-small cell lung cancer (NSCLC). These cells are adherent, exhibit an epithelial morphology, and carry a KRAS G12S mutation while retaining a wild-type p53 status. As alveolar basal epithelial cells, A-549 cells retain key features of lung epithelium and are particularly suited for studying the interplay between oncogenic drivers and metabolic signaling pathways relevant to lung adenocarcinoma.
APPL1 functions as a molecular adaptor that couples activated plasma membrane receptors to intracellular signaling cascades. Upon insulin or adiponectin stimulation, APPL1 binds the p85 regulatory subunit of PI3K (PIK3R1) and recruits the catalytic p110 subunit, facilitating PIP3 production and PDK1-mediated AKT phosphorylation. Activated AKT phosphorylates mTOR and GSK3??, promoting cell survival and proliferation. APPL1 also interacts with Rab5 to regulate early endosome dynamics and link receptor endocytosis to signal propagation. Additional regulatory inputs from NGF, FSH, and DHT place APPL1 at the intersection of multiple pathways, including NF-??B and adipocytokine cascades. Through homodimerization and interactions with GIPC1 and OCRL, APPL1 orchestrates spatially coordinated signaling.
In the A-549 background, APPL1 knockout significantly perturbs insulin- and adiponectin-stimulated AKT activation, thereby impairing downstream mTORC1 activity and GSK3?? inhibition. Because A-549 cells harbor an activating KRAS mutation, the loss of APPL1 may reveal context-dependent dependencies on the PI3K/AKT pathway for anchorage-independent growth and survival. This model allows researchers to examine how adaptor proteins modulate oncogenic signaling and endosomal trafficking in NSCLC, potentially affecting responses to targeted therapies such as gefitinib or cisplatin. Consequently, APPL1 knockout A-549 polyclonal cells offer a physiologically relevant platform for investigating metabolic reprogramming and drug resistance mechanisms.
Key applications include dissecting insulin and adiponectin signaling in lung cancer, studying the role of APPL1 in endosomal sorting and receptor recycling, and evaluating the impact of APPL1 loss on cell proliferation, migration, and invasion. Representative assays for this line include insulin-stimulated AKT phosphorylation western blotting, glucose uptake measurements, cell viability (MTT/CCK-8) assays, phospho-signaling arrays, and co-immunoprecipitation of APPL1 interaction partners. Additionally, these cells are valuable for high-throughput drug sensitivity screening and for assessing APPL1 as a therapeutic vulnerability in KRAS-driven NSCLC. Researchers seeking to incorporate this knockout model into their studies are invited to contact Ascent Research for additional information.
